Physician-Reported Experience and Understanding of Adverse Event Attribution in Cancer Clinical Trials
Objectives: To report the results of a survey conducted among Mayo Clinic medical oncologists, hematologists, and cancer prevention specialists to better understand the current practice of determining whether an adverse event that a patient experience in a clinical trial is related to the drug under...
Main Authors: | Jennifer G. Le-Rademacher, PhD, Elizabeth M. Storrick, BA, Aminah Jatoi, MD, Sumithra J. Mandrekar, PhD |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2019-06-01
|
Series: | Mayo Clinic Proceedings: Innovations, Quality & Outcomes |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2542454819300074 |
Similar Items
-
Adverse Event Burden Score—A Versatile Summary Measure for Cancer Clinical Trials
by: Jennifer G. Le-Rademacher, et al.
Published: (2020-11-01) -
Remarks on the design and analyses of longitudinal studies for cancer patients with anorexia and weight loss
by: Jennifer G. Le‐Rademacher, et al.
Published: (2019-12-01) -
Neutrophil Counts in Healthy South African Infants: Implications for Enrollment and Adverse Event Grading in Clinical Trials in an African Setting
by: Anthonet Koen, MBBCh, et al.
Published: (2019-01-01) -
Toward Prevention of Adverse Events Using Anticipatory Analytics
by: Joseph Norman, PhD,, et al.
Published: (2020-06-01) -
Impact of Pharmacogenomic Information on Values of Care and Quality of Life Associated with Codeine and Tramadol-Related Adverse Drug Events
by: Ye Zhu, MD, PhD, et al.
Published: (2021-02-01)